Cutting monkeypox vaccine dosage is no easy fix, officials say

A new dose-sparing technique to extend the US supply of Bavarian Nordic’s monkeypox vaccine has been met with widespread safety concerns, with the vaccine maker’s CEO expressing ”reservations” about the method.


The US government’s solution to the monkeypox vaccine shortage is so far only causing headaches for strained public health departments as the outbreak continues to grow in scale and scope.

The so-called dose-sparing strategy allows those giving out the vaccine to use just one-fifth of what’s traditionally given in attempt to squeeze more doses out of the existing supply. While sounding good in theory, the move requires “a significant shift in operations” for local health departments, Allison Arwady, Chicago’s public health commissioner, said during a Big Cities Health Coalition meeting. And it could be weeks before clinicians actually start employing this strategy, she said.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs